2011

DG Trade State of Play reveals EU's ambitions for IP protection in FTAs

European drug regulator challenged over revolving door case involving former Director

Corporate funding linked to EU patient & consumer groups policy

2010

EMA reviews transparency criteria

HAI research on financial disclosure featured in article: European politicians' call for greater transparency

HAI Europe Statement: EMA talks the ‘conflicts of interest’ talk, but will it walk the walk?

Dutch Minister of Health supports HAI E's financial transparency recommendations to EMA

Report exposes how Big Pharma has hijacked EU-India trade deal

In perspective: EMA comments on HAI Europe's survey of financial disclosure

Impact of HAI Europe survey results: Two weeks on

HAI Europe survey reveals new data on financial transparency of patient and consumer organisations

HAI Europe recommendations for improved conflict of interest declarations at EMA

ISDB & MiEF criticize EMA over conflict of interest procedures

Review of conflict of interest policies in three European medicines regulation agencies

EU Ombudsman: Transparency rules apply to all documents held by EMA

European Medicines Agency faces tough questions about patient groups' transparency

HAI hosts essay competition for students

Patient Groups need dose of transparency

Generic prescribing policies 1 – ABPI 0

Snooping CEO unveils conflicts of interest at the European Medicines Agency

Finnish study: Drug companies see added value of patient group sponsorship